Factitious increases in serum testosterone concentrations related to phenylbutazone therapy.
We report 6 additional observations of a drug/hormone assay interaction between serum testosterone and phenylbutazone intake. This interaction had been described previously only once. We discuss its potential mechanisms, based upon our experimental findings, and its clinical implications.
Uzzan
Bernard
B
Department of Pharmacology, AP-HP, hôpital Avicenne, 125 route de Stalingrad, 93009-Bobigny, and Paris-XIII University, France. bernard.uzzan@avc.aphp.fr
Dumont-Fischer
Dominique
D
Lahlou
Najiba
N
Bihan
Hélène
H
Boissier
Marie-Christophe
MC
Alvarez
Jean-Claude
JC
Perret
Gérard-Yves
GY
Cohen
Régis
R
D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010653:Phenylbutazone / Q000009:adverse effects* / Q000627:therapeutic use; D011446:Prospective Studies; D013739:Testosterone / Q000097:blood*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D013739:Testosterone; D010653:Phenylbutazone